Stock Events

MEDTRONIC 

€72.21
3494
+€0.52+0.73% Friday 12:14

統計

當日最高
72.21
當日最低
72.21
52週最高
84.54
52週最低
67.98
成交量
15
平均成交量
50
市值
-
市盈率
-
股息收益率
3.62%
股息
2.61

即將到來

股息

3.62%股息收益率
10年增長
10.95%
5年增長率
6.43%
3年增長率
7.05%
1年增長率
2.44%

收益

23May確認
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
1.02
1.17
1.32
1.46
預期每股收益
1.3407859999999998
實際每股收益
1.3500328

人們還關注

此列表基於在 Stock Events 上關注 1MDT.MI 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Show more...
首席執行官
Mr. Geoffrey Straub Martha
員工
95000
國家
IE
ISIN
IE00BTN1Y115
WKN
000A14M2J

上市公司